Initial Management of Post-Infectious Irritable Bowel Syndrome (PI-IBS)

Diagnostic Confirmation

• The American Gastroenterological Association recommends confirming PI-IBS diagnosis using Rome IV criteria: recurrent abdominal pain at least 1 day/week in the last 3 months, with symptom onset immediately following resolution of acute infectious gastroenteritis 1, 2
• Infectious gastroenteritis should be defined by positive stool culture or presence of ≥2 acute symptoms: fever, vomiting, or diarrhea 2
• Limited baseline investigations should include full blood count, C-reactive protein or ESR, coeliac serology, and faecal calprotectin (if diarrhea and age <45 years) 3, 4

First-Line Management Strategies

Dietary Interventions

• The British Dietetic Association recommends providing standard first-line dietary advice to all patients with PI-IBS 4
• The British Dietetic Association suggests recommending soluble fiber supplementation (e.g., ispaghula) starting at low dose (3-4g/day) and gradually increasing to avoid bloating 4
• The British Dietetic Association advises avoiding insoluble fiber (e.g., wheat bran) as it may exacerbate symptoms 4
• Consider a low FODMAP diet as second-line dietary therapy under supervision of a trained dietitian 4

Lifestyle Modifications

• The American Gastroenterological Association recommends regular exercise for all patients with PI-IBS 4
• Establish regular times for defecation to help regulate bowel function, as recommended by the European Society of Gastroenterology 5
• Implement proper sleep hygiene practices as sleep disturbances can worsen symptoms, according to the European Society of Gastroenterology 5

Pharmacological Treatment Based on Predominant Symptoms

For IBS-D (Diarrhea-predominant)

• The American Gastroenterological Association recommends starting with loperamide for diarrhea control, carefully titrating the dose to avoid side effects like constipation 4
• Consider ondansetron or ramosetron as second-line options, as suggested by the American College of Gastroenterology 1, 2
• Eluxadoline may be used for more severe diarrhea symptoms, according to the American College of Gastroenterology 1, 2

For IBS-M (Mixed type)

• The British Society of Gastroenterology recommends considering antispasmodics for abdominal pain relief 4
• SSRIs can be beneficial for global symptom improvement, as recommended by the American Psychiatric Association 1, 2
• Psychological therapy should be considered early in the treatment algorithm, according to the American Psychological Association 1, 2

Second-Line Treatments

Neuromodulators

• The European Society of Gastroenterology recommends low-dose tricyclic antidepressants for abdominal pain in PI-IBS and may help with sleep disturbances 4, 6
• SSRIs at therapeutic doses should be considered first-line for patients with co-occurring depression or anxiety, as suggested by the National Institute for Health and Care Excellence 6

Psychological Interventions

• Brain-gut behavioral therapies (BGBTs) such as cognitive behavioral therapy, gut-directed hypnotherapy, and mindfulness-based stress reduction are effective for symptom management, according to the American Psychological Association 5, 6
• Self-management approaches including education about the brain-gut connection can help patients understand their condition, as recommended by the European Society of Gastroenterology 6

Monitoring and Follow-up

• Reassess symptoms after 4-6 weeks of initial treatment, as recommended by the American Gastroenterological Association 1, 2
• Regularly assess both gastrointestinal and psychological symptoms to evaluate treatment response, according to the National Institute for Health and Care Excellence 6
• Adjust treatment strategies based on symptom evolution, as suggested by the European Society of Gastroenterology 6

Common Pitfalls to Avoid

• Focusing only on gastrointestinal symptoms while neglecting psychological factors, as warned by the American Psychological Association 5
• Overreliance on medications without addressing lifestyle and dietary factors, according to the European Society of Gastroenterology 5
• Implementing restrictive diets without proper supervision, as cautioned by the British Dietetic Association 5, 6
• Using low-dose TCAs as monotherapy in patients with established mood disorders, as warned by the National Institute for Health and Care Excellence 6

Treatment of Post-Infectious Irritable Bowel Syndrome (PI-IBS)

Initial Patient Education and Diagnostic Confirmation

• The American Gastroenterological Association recommends explaining IBS as a disorder of gut-brain interaction, emphasizing that symptoms result from visceral hypersensitivity, disordered immune reactions, and persistent low-grade inflammation following infection, and setting realistic expectations: cure is unlikely, but substantial improvement in symptoms and quality of life is achievable 7

First-Line Lifestyle and Dietary Interventions

• Regular physical exercise improves gastrointestinal symptoms and has beneficial effects lasting up to 5 years, according to the American Gastroenterological Association 7

Symptom-Directed Pharmacological Treatment

• The American College of Gastroenterology recommends considering rifaximin as second-line therapy for patients without significant constipation: 550 mg three times daily for 14 days, with a 47% response rate for combined abdominal pain and stool consistency improvement versus 39% with placebo 8
• The American Gastroenterological Association suggests using antispasmodics or peppermint oil as first-line treatment for abdominal pain 9
• Escalating to low-dose tricyclic antidepressants (TCAs) if antispasmodics fail is recommended by the American College of Gastroenterology, as TCAs provide dual benefit: pain relief and improvement in sleep disturbances 8

Psychological Interventions

• The American Psychological Association recommends offering cognitive behavioral therapy (CBT) or mindfulness-based therapy early in the treatment algorithm, particularly for patients with psychological comorbidity, with improved quality of life by 32-39% in IBS patients compared to controls 8